VIVS VivoSim Labs Inc.
- Stocks
- Healthcare
- NASDAQ: VIVS
Price (delayed)
$1.8
Market cap
$4.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
-$3.7M
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are
Highlights
The EPS has soared by 99% year-on-year and by 88% since the previous quarter
VIVS's gross profit has soared by 96% year-on-year
The equity has increased by 43% year-on-year but it has declined by 9% since the previous quarter
Key stats
What are the main financial stats of VIVS
Market
Valuations
Earnings
Shares outstanding
2.6M
Market cap
$4.68M
Enterprise value
-$3.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
31.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-26.03
Revenue
$142,000
Gross profit
$139,000
Operating income
-$12.15M
Net income
-$1.99M
EBIT
-$1.97M
EBITDA
-$1.17M
Free cash flow
-$1.43M
Per share
Balance sheet
Liquidity
EPS
-$0.2
EPS diluted
-$0.2
Free cash flow per share
-$0.57
Book value per share
$3.67
Revenue per share
$0.06
TBVPS
$4.78
Total assets
$11.98M
Total liabilities
$2.44M
Debt
$822,000
Equity
$9.54M
Working capital
$7.54M
Debt to equity
0.09
Current ratio
4.52
Quick ratio
4.78
Net debt/EBITDA
7.15
Margins
Efficiency
Dividend
EBITDA margin
-825.4%
Gross margin
97.9%
Net margin
-1,399.3%
Operating margin
-8,552.8%
Return on assets
-21.4%
Return on equity
-33%
Return on invested capital
-143.8%
Return on capital employed
-20.1%
Return on sales
-1,389.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIVS stock price
How has the VivoSim Labs stock price performed over time
Intraday
-3.23%
1 week
3.03%
1 month
-7.22%
1 year
-73.29%
YTD
-67.39%
QTD
22.45%
Financial performance
How have VivoSim Labs's revenue and profit performed over time
Revenue
$142,000
Gross profit
$139,000
Operating income
-$12.15M
Net income
-$1.99M
Gross margin
97.9%
Net margin
-1,399.3%
VIVS's gross profit has soared by 96% year-on-year
The revenue has soared by 95% YoY
VIVS's net margin has surged by 93% year-on-year and by 19% since the previous quarter
The net income has surged by 86% year-on-year and by 20% since the previous quarter
Price vs fundamentals
How does VIVS's price correlate with its fundamentals
Growth
What is VivoSim Labs's growth rate over time
Valuation
What is VivoSim Labs stock price valuation
P/E
N/A
P/B
0.49
P/S
31.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-26.03
The EPS has soared by 99% year-on-year and by 88% since the previous quarter
The stock's price to book (P/B) is 91% less than its last 4 quarters average of 5.6 and 79% less than its 5-year quarterly average of 2.4
The equity has increased by 43% year-on-year but it has declined by 9% since the previous quarter
The revenue has soared by 95% YoY
The P/S is 36% below the last 4 quarters average of 51.4
Efficiency
How efficient is VivoSim Labs business performance
The ROS has soared by 93% year-on-year and by 19% since the previous quarter
VIVS's return on assets has surged by 86% year-on-year and by 25% since the previous quarter
The ROE has soared by 85% YoY and by 30% from the previous quarter
VIVS's return on invested capital has surged by 69% year-on-year and by 7% since the previous quarter
Dividends
What is VIVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIVS.
Financial health
How did VivoSim Labs financials performed over time
VIVS's quick ratio has soared by 52% YoY and by 43% from the previous quarter
The total liabilities has declined by 41% since the previous quarter and by 13% year-on-year
VIVS's debt is 91% smaller than its equity
The debt to equity has plunged by 53% YoY and by 10% from the previous quarter
The equity has increased by 43% year-on-year but it has declined by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.